Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 9/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 9/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 9/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21954933 | 0.89 | ITGB1 (0.41) | ITGB1ITGA4ITGB7L3MBTL1HTT | |
| SCHEMBL21954932 | 0.89 | ITGB1 (0.41) | ITGB1ITGA4ITGB7L3MBTL1HTT | |
| SCHEMBL29736325 | 0.82 | ITGB1 (0.36) | ITGB1ITGA4ITGB7PTGS2L3MBTL1 | |
| SCHEMBL22016797 | 0.82 | ITGB1 (0.36) | ITGB1ITGA4ITGB7PTGS2L3MBTL1 | |
| SCHEMBL5162201 | 0.76 | ITGB1 (0.55) | ITGB1ITGA4ITGB7PTGS2 | |
| SCHEMBL22016795 | 0.75 | PTGS2 (0.34) | PTGS2L3MBTL1MAPT | |
| SCHEMBL29736282 | 0.74 | MEN1 (0.36) | PTGS2LMNA | |
| SCHEMBL20387784 | 0.73 | ITGA4 (0.53) | ITGB1ITGA4ITGB7PTGS2LMNA | |
| SCHEMBL5163380 | 0.73 | ITGA4 (0.53) | ITGB1ITGA4ITGB7PTGS2LMNA | |
| SCHEMBL22038823 | 0.73 | ITGB1 (0.35) | ITGB1ITGA4ITGB7L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.